Tacrolimus European Pharmacopoeia Monograph [hot] -

Tacrolimus has multiple crystalline forms (Forms I, II, and amorphous). The monograph’s IR identification implicitly requires the thermodynamically stable form. An incorrect polymorph can lead to dissolution failure in generic capsules.

A specific stationary phase (usually C18 or a specialized reverse-phase column) is used.

While not strictly for testing, this section describes Tacrolimus as a white or almost white crystalline powder, practically insoluble in water, freely soluble in ethanol and methanol. This informs solvent choices for HPLC analysis and formulation. tacrolimus european pharmacopoeia monograph

The European Pharmacopoeia monograph for Tacrolimus (monograph number typically found under general chapter references) follows the standard template established by the European Directorate for the Quality of Medicines & HealthCare (EDQM). It comprises several critical sections:

This article provides an in-depth exploration of the Tacrolimus European Pharmacopoeia monograph. We will dissect the scientific principles behind its testing requirements, the stringent limits on impurities, and the critical role this document plays in ensuring patient safety across the European Union and beyond. Tacrolimus has multiple crystalline forms (Forms I, II,

To fully comply with the monograph, a quality control laboratory must have:

The "Identification" section is designed to confirm that the substance tested is indeed Tacrolimus. The monograph typically relies on two primary methodologies: A specific stationary phase (usually C18 or a

The monograph opens by defining Tacrolimus as a substance that contains not less than 97.0% and not more than 102.0% of C₄₄H₆₉NO₁₂, calculated on the dried basis. It identifies the substance chemically as 3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[(1E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propen-1-yl)-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone .